CA2568640C - Pharmaceutical composition containing irbesartan - Google Patents

Pharmaceutical composition containing irbesartan Download PDF

Info

Publication number
CA2568640C
CA2568640C CA2568640A CA2568640A CA2568640C CA 2568640 C CA2568640 C CA 2568640C CA 2568640 A CA2568640 A CA 2568640A CA 2568640 A CA2568640 A CA 2568640A CA 2568640 C CA2568640 C CA 2568640C
Authority
CA
Canada
Prior art keywords
composition
irbesartan
tablet
weight
povidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2568640A
Other languages
French (fr)
Other versions
CA2568640A1 (en
Inventor
Gershon Kolatkar
Erela Zisman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2568640A1 publication Critical patent/CA2568640A1/en
Application granted granted Critical
Publication of CA2568640C publication Critical patent/CA2568640C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85%
of the Irbesartan is dissolved within about 30 minutes using USP apparatus 2, placing the tablet in 1000mL of 0.1N hydrochloric acid at 37~C with paddle speed of 50 rpm. The formulation can optionally contain at least one additional active ingredient.

Description

PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN

FIELD OF THE INVENTION
[001] This application relates to pharmaceutical compositions containing irbesartan, and to pharmaceutical compositions containing irbesartan and hydrochlorothiazide.
BACKGROUND OF THE INVENTION
[002] Irbesartan is chemically described as 2-butyl-3-[[29-(I H-tetrazol-5-yl) [ 1,19-biphenyl]-4-yl] methyl] 1,3-diazaspiro[4,4] non-l-en-4-one, also as 2-n-butyl-spirocyclopentane-I-[(2'-(tetrazol-5-y))biphenyl-4-yl)methyl) -2-imidazolin-5-one, also as 2-butyl-3-[[2'-(1 H-tetrazol-5-yl) [1,1'-biphenyl]-4-y]methyl]-1,3-diazaspiro [4,4] non-I-en-4-one. Its empirical formula is C25H28N6O, and it has the following structure:

N NON
, \ NH
U N(n-C4H9) I
(CFI2J
[003J Irbesartan has a molecular weight of 428.5. The compound is described in U.S.
Patent 5,270,317.
[0041 In the United States, irbesartan is available for oral administration tablets containing 75 mg, 150 mg, or 300 mg of irbesartan, which are sold under the trade name AVAPRO The drug also is formulated as 150 and 300 mg tablets that also include 12.5 mg hydrochlorothiazide, which are sold under the trade name AVALIDEE
[0051 As noted in United States Patent 6,342,247, irbesartan is a fluffy material with relatively low bulk, and tap densities. In addition, irbesartan has certain undesirable flow characteristics. These properties make it difficult to formulate a large amount of the drug into a small tablet. Indeed, the '247 patent describes an oral formulation of irbesartan containing only up to 70% of the drug. Accordingly, there is a need for an improved formulation of irbesartan that contains a higher amount of the active ingredient.

SUMMARY OF THE INVENTION
1006] This invention relates to pharmaceutical compositions comprising irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85% of the irbesartan is dissolved within about 30 minutes, preferably greater than about 80% of the irbesartan is dissolved within about 10 minutes, using USP apparatus 2, placing the tablet in 1000mL of 0.1 N hydrochloric acid at 37 C
with paddle speed of 50 rpm. In another embodiment, the invention provides an oral formulation of two active pharmaceutical agents, irbesartan, and a diuretic, such as hydrochlorothiazide. These aspects and advantages, as well as additional inventive features, will be apparent upon reading the following detailed description.
The formulations can optionally contain at least one additional active ingredient.

DETAILED DESCRIPTION OF THE INVENTION
1007] The invention provides an oral formulation comprising irbesartan, and it provides an oral composition comprising irbesartan and hyhdrochlorothiazide. The irbesartan for inclusion in the inventive formulation can be manufactured according to any desired method, many of which are known to those of ordinary skill in the an. Examples of suitable methods to manufacture irbesartan are described in U.S. Patent 5,270,317, Hydrochlorothiazide is also well known and can be manufactured by methods known in the art.
[008] In one embodiment, the invention provides an oral formulation comprising irbesartan that includes at least about 70% irbesartan w/w. Preferably, the formulation includes at least about 75% w/w irbesartan, and more preferably the formulation includes from about 75% w/w to about 80%w/w irbesartan. A higher relative amount or concentration of irbesartan can be included, if desired.
1009] In another embodiment, the invention provides an oral formulation comprising irbesartan which exhibits an improved dissolution profile according to the U.S.
Pharmacopeia, using USP apparatus 2, placing the tablet in 1000mL of 0.1 N
hydrochloric acid at 37 C with paddle speed of 50 rpm. In some embodiments of the invention, the oral formulation comprising irbesartan exhibits a dissolution profile according to which greater than about 80% of the irbesartan is dissolved within about 10 minutes, and even more preferably greater than about 85% of the irbesartan is dissolved within about 10 minutes.
The present invention provides, in another aspect, an oral formulation comprising irbesartan which exhibits a dissolution profile according to which at least about 75% of the irbesartan is dissolved within about 5 minutes, at least about 85% of the irbesartan is dissolved within about 10 minutes and at least about 95% of the irbesartan is dissolved in about 20 minutes.
In accordance with another aspect of the invention, an oral formulation comprising irbesartan is provided which exhibits a dissolution profile according to which at least 97%
of irbesartan is dissolved within 30 minutes. In some embodiments of the invention, the oral formulation comprising irbesartan exhibits a dissolution profile according to which greater than about 85% of the irbesartan is dissolved within about 30 minutes.
[0010] In addition to irbesartan, the oral formulation can include at least one additional active agent or combination of additional active agents. A preferred active agent to include in the formulation is a diuretic agent, such as hydrochlorothiazide, bendroflumethiazide, benzthiazide, chlorothiazide, chlorthalidone, cyclothiazide, hydroflumethiazide, methyclothiazide, metolazone, polythiazide, quinethazone, and trichlormethiazide.
Preferably, at least one diuretic is a thiazidic such as chlorothiazide and hydrochlorothiazide. Hydrochlorothiazide, the 3,4-dihydro derivative of chlorothiazide, is the preferred diuretic for inclusion in the inventive composition. Its chemical name is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8C1N3O4S2. Hydrochlorothiazide can be prepared by methods known to those of skill in the art The amount of diuretic, such as hydrochlorothiazide is included in the formulation can be varied to achieve the desired therapeutic effect. In a preferred embodiment, the amount of diuretic is from about 3% to about 7% by weight of the formulation, more preferably, 3.32 to about 6.65% by weight of the formulation. The preferred diuretic is hydrochlorothiazide.
[0011] In addition to irbesartan and optional additional active ingredient or combination of additional active ingredients, the formulation contains at least one pharmaceutically acceptable excipient. In this context, the term "excipient" refers to pharmaceutically acceptable chemicals known to those of ordinary skill in the art of pharmacy to aid the administration of the medicinal agent. Preferable excipients for inclusion in the inventive formulation include binders, surfactants, diluents, disintegrants, antiadherents, and lubricants.
[0012] Preferably, the inventive composition comprises, one or more binders.
Suitable "binders" can be selected from those capable of facilitating granulation of the irbesartan into larger, denser, and more free-flowing particles. Preferred binders include povidone (most preferably employed in the range of 1.0 - 7.0% by weight), pregelatinized starch (most preferably employed in the range of 1.0 - 10.0% by weight), algenic acid (most preferably employed in the range of 1.0 - 7.0% by weight) or sodium alginate (most preferably employed in the range of 1.0 - 5.0% by weight), cellulose or cellulose derivatives such as carboxymethylcellulose sodium (most preferably employed in the range of 1.0 -6.0% by weight), ethylcellulose (most preferably employed in the range of 1.0 - 4.0%
by weight), hydroxyethyl cellulose (most preferably employed in the range of 1.0 - 5.0% by weight), hydroxypropyl cellulose (most preferably employed in the range of 1.0 - 7.0%
by weight), hydroxypropyl methylcellulose (most preferably employed in the range of 1.0 -6.0% by weight)or methylcellulose (most preferably employed in the range of 1.0 - 6.0%
by weight), gelatin (most preferably employed in the range of 1.0 - 7.0% by weight). Other binders known to those of skill in the art can be employed. Preferably, the binder is povidone, most preferably, PVP K-30, and, where present, it can represent of from about 2.0% w/w to about 2.15% w/w, most preferably 2.13% w/w, of the formulation.
Another preferred binder is pregelatinized starch, most preferably, starch 1500 and, where present, the pregelatinized starch (starch 1500) typically represents from about 6.35%, most preferably, 6.38% w/w, and about 8.0 % w/w of the formulation.
[00131 The inventive composition preferably includes at least one disintegrant. Suitable "disintegrants" can be selected from one or more components, which facilitate the break up of a tablet prepared from the composition when placed in contact with an aqueous medium.
Any suitable disintegrant can be employed within the invetive formulation.
Preferred disintegrant are croscarmellose sodium, such as Ac-Di-Sol (most preferably employed in the range of 1.0 - 7.0% by weight), algenic acid (most preferably employed in the range of 1.0 - 7.0% by weight) or sodium alginate (most preferably employed in the range of 1.0 -7.0% by weight), carboxymethylcellulose sodium (most preferably employed in the range of 1.0 - 7.0% by weight), crospovidone (most preferably employed in the range of 1.0 -7.0% by weight), sodium starch glycolate (most preferably employed in the range of 1.0 -7.0% by weight), pregelatinized starch (most preferably employed in the range of 1.0 -7.0% by weight).. Where present, typically croscannellose. Where present, preferably, croscarmellose sodium (Ac-Di-Sol) represents from about 3.15%, preferably 3.19%, w/w to about 5.0%, preferably 4.0%, w/w of the formulation.
[00141 The inventive composition preferably includes at least one surfactant.
Suitable "surfactants" include compounds which aid in wetting so as to enhance dissolution. Any suitable surfactant can be employed in the inventive formulation. Preferred surfactants are sodium lauryl sulfate (most preferably employed in the range of 0.2-6.0% by weight), poly(oxyethylene), poly(oxypropylene) block co-polymers such as poloxamers, especially Poloxamer 188 (most preferably employed in the range of 0.2-6.0% by weight).
Where present, the Poloxamer 188 typically represents from about 1.00%, preferably 1.06%, w/w to about 2.0% w/w of the formulation.
[00151 The formulation preferably includes one or more diluents. Suitable "diluents"
include compounds which are capable of providing bulk to obtain a desired mass, such as desired tablet mass. Any suitable diluent can be employed in the inventive formulation.
Preferred diluents are microcrystalline cellulose, such as AvicelPH 102 FMC, inorganic phosphates such as dibasic calcium phosphate, sugars such as lactose hydrous or lactose anhydrous and mannitol. Diluents are preferably included in the range of 2-10%
by weight of the formulation. Where present, the microcrystalline cellulose typically represents from about 1% w/w to about 7.5% w/w of the formulation. For formulations that include only irbesartan as the active pharmaceutical agent, microcrystalline cellulose, where present, typically represents from about 1.9% w/w, to about 7.5% w/w of the formulation. For formulations which include irbesartan and diuretics, such as hydrochlorothiazide, as the active pharmaceutical agents, microcrystalline cellulose, when present, typically represents from about 1.9% w/w to about 6% w/w of the formulation. In some embodiments of the invention, microcrystalline cellulose, preferably is present in an amount of from about 1.97% w/w to about 5.3% w/w of the formulation, preferably 5.29% w/w. In other embodiments, microcrystalline cellulose preferably is present in an amount of from about 3.56% w/w to about 5.96% w/w of the formulation.
[00161 The inventive composition can further include at lease one antiadherent. Suitable "antiadherents" include compounds that contribute to the flowability of the formulation.
Any suitable antiadherents can be employed in the inventive formulation.
Preferred antiadherents are silicon dioxide, such as Syloid 244 (most preferably employed in the range of 0.2-2.0% by weight) or talc (most preferably employed in the range of 0.5-5.0% by weight). Where present, the silicon dioxide typically represents from about 0.4% w/w to about 0.5% w/w of the formulation.
[00171 The composition of the present invention preferably includes at least one lubricant. Suitable "lubricants" include compounds that assist in preparing the desired fonn of the formulation for administration, such as tabletting. Any suitable lubricant can be employed in the inventive formulation. Preferred lubricants are fatty acids or fatty acid derivatives such as calcium stearate (most preferably employed in the range of 0.5-2.0% by weight), glyceryl monostearate (most preferably employed in the range of 0.5-2.0% by weight), glyceryl palmitostearate (most preferably employed in the range of 0.5-2.0% by weight), magnesium stearate (most preferably employed in the range of 0.2-2.0%
by weight), sodium lauryl sulfate (most preferably employed in the range of 0.5-2.0% by weight), sodium stearyl furnarate (most preferably employed in the range of 0.5-2.0% by weight), zinc stearate, stearic acid (most preferably employed in the range of 0.5-3.0% by weight), hydrogenated vegetable oil (most preferably employed in the range of 0.5-5.0% by weight), polyalkylene glycols such as polyethylene glycol (most preferably employed in the range of 1.0-5.0% by weight) talc (most preferably employed in the range of 1.0-5.0% by weight). Where present, the magnesium stearate represents from about 1.0% w/w to about 1.1% w/w of the formulation, preferably from about 1.0% w/w to about 1.06% w/w of the formulation.
[00181 Preferred compositions according to the invention is set forth in Table 1:
ACM

Preferred Ingredients Component Concentration Range (% w/w) Irbesartan Active drug 75-79.79 Pregelatinized starch (starch 1500) Binder 6.38-8.0 Povidone (PVP K-30) Binder 2-2.13 Poloxamer 188 Surfactant 1.06-2.0 Microcrystalline Cellulose (Avicel PH 102) Diluent 5.96-7.5 Croscarmellose Sodium (Ac-Di-Sol) Disintegrant 3.19-4.0 Silicon Dioxide (syloid 244) Antiadherent 0.43-0.5 Magnesium Stearate Lubricant 1.0-1.06 [0019] The inventive formulation includes any form of irbesartan for oral administration, or any form of irbesartan and diuretic, such as hydrochlorothiazide, such as a tablet, caplet, capsule or the like. The preferred formulation is a tablet. Most preferably, tablets of the present invention contain (per tablet) 300mg of irbesartan. The total weight of the tablet preferably is between 376mg and 400mg.
[0020] Formulations containing irbesartan can be prepared by any suitable method. A
preferred method for forming a tablet formulation comprising irbesartan according to one embodiment of the present invention is by a wet granulation process. By way of example, the irbesartan formulation can be prepared according to the following method:
1. Irbesartan is partially granulated with granulating solution of povidone in purified water using high shear mixer.
2. Pregelatinized starch is mixed with the mixture of step 1 in high shear mixer.
3. The blend of step 2 is granulated with a granulating solution of Poloxamer 188 in purified water using high shear mixer.
4. The granules formed in step 3 are dried in fluid bed dryer.
5. The dried granules are sized by passing them through an oscillating granulator.
6. The milled dried granulate of step 5 is mixed with microcrystalline cellulose, croscarmellose sodium and silicon dioxide in a blender.
7. Magnesium stearate is added to the mixture of step 6 and mixed.
8. The mixture from step 7 is compressed to form tablets using a tablet press.
[0021] Formulations that include irbesartan and a diuretic, such as hydrochlorothiazide, can include binders such as povidone, without a surfactant, and they can include binders such as povidone and surfactant, such as poloxamer, preferably Poloxamer 188.
In some preferred embodiments of the present invention, povidone comprises from about 2 to about 2.5% w/w and preferably 2.13% w/w of a composition comprising irbesartan and diuretic such as hydrochlorothiazide. In another preferred embodiment of a composition comprising irbesartan and diuretic such as hydrochlorothiazide according to the present invention, the composition comprises povidone in an amount of from about 2 to about 2.5% w/w, more preferably 2.13% w/w of the composition, and poloxamer of from about 1 to about 1.2%
w/w, more preferably 1.06% w/w of the composition.
[0022] Formulations containing irbesartan and diuretic can be prepared by any suitable method. A preferred method for forming a tablet formulation comprising irbesartan and hydrochlorothiazide according to one embodiment of the present invention is by a wet granulation process. By way of example, a formulation comprising irbesartan and hydrochlorothiazide can be prepared according to the following method:
1. Irbesartan and hydrochlorothiazide are mixed using high shear mixer.
2. Pregelatinized Starch is mixed with the mixture of step 1 in high shear mixer.
3. The mixture from step 2 is granulated with granulating solution of povidone in purified water using high shear mixer.
4. The granules are dried in fluid bed dryer.
5. The dried granules are sized by using oscillating granulator.
6. The milled dried granulate is mixed with microcrystalline cellulose, croscarmellose sodium and silicon dioxide in a blender.
7. The mixture of step 6 is mixed with magnesium stearate as a lubricant.
8. The mixture from step 7 is mixed to form tablets using tablet press.
[0023] By way of further example, a formulation comprising irbesartan and hydrochlorothiazide can be prepared according to the following method:
1. Irbesartan and hydrochlorothiazide are mixed using high shear mixer.
2. The mixture of step 1 is partially granulated with a granulating solution of povidone in purified water using high shear mixer.' 3. Pregelatinized Starch is mixed with the mixture of step 2 in high shear mixer.
4. The mixture from step 3 is granulated with granulating solution of Poloxamer 188 in purified water using high shear mixer.
5. The granules are dried in fluid bed dryer.
6. The dried granules are sized by using oscillating granulator.
7. The milled dried granulate is mixed with microcrystalline cellulose, croscarmellose sodium and silicon dioxide in a blender.
8. The mixture of step 7 is mixed with magnesium stearate as a lubricant.
9. The mixture from step 8 is mixed to form tablets using tablet press.

[0024] The tablets comprising irbesartan and hydrochlorothiazide prepared from the compositions of the present invention preferably contain (per tablet), 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide, or 300mg of irbesartan and 12.5 mg of hydrochlorothiazide. Typically, the total weight of the tablet comprising 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide is 188 mg and the total weight of the tablet comprising 300 mg irbesartan and 12.5 mg hydrochlorothiazide is 376mg to 400mg.
[0025] Preferred compositions according to the invention comprising irbesartan and hydrochlorothiazide are as follows:

Preferred Ingredients Component Concentration Range (% w/w) Irbesartan Active drug 75.0 -79.79 Hydrochlorothiazide Active drug 3.32-6.65 Pregelatinized starch (starch 1500) Binder 3.19-5.32 Povidone (PVP K-30) Binder 2.0- 2.13 Microcrystalline Cellulose (Avicel PH 102) Diluent 3.56 -5.96 Croscarmellose Sodium (Ac-Di-Sol) Disintegrant 3.19-4.0 Silicon Dioxide (syloid 244) Antiadherent 0.4-0.43 Magnesium Stearate Lubricant 1.0-1.06 [0026] The following examples are presented to illustrate certain features of the invention, but these should not be understood to limit the scope of the invention.

[0027] This example illustrates the preparation of tablets containing 75%
irbesartan.
[0028] Tablets containing irbesartan were prepared in three potencies using the composition of the present invention described in Table 2.
[0029] 1. 75mg irbesartan with a total weight of 100mg per tablet.
[0030] 2. 150mg irbesartan with total weight of 200mg per tablet.
[0031] 3. 300mg irbesartan with a total weight of 400mg per tablet.

Ingredients Component concentration (% W/W) Irbesartan Active drug 75 Povidone (PVP K-30) Binder 2.0 Pregelatinized Starch (Starch 1500) Binder 8.0 Poloxamer 188 Surfactant 2.0 Microcrystalline Cellulose (Avicel PH 102) Diluent 7.5 Croscarmellose Sodium (Ac-Di-Sol) Disintegrant 4.0 Silicon Dioxide (syloid 244) Antiadherent 0.5 Magnesium Stearate Lubricant 1.0 Total 100.0 100.0 [00321 Using the above formulation, tablets were prepared by an aqueous wet granulation process, in accordance with the method described above. The partial granulation of irbesartan with granulating solution of povidone in purified water was carried out in a high shear mixer (Diosna). This mixture was mixed with pregelatinized starch and then granulated with the granulating fluid of Poloxamer 188 in purified water. The granules obtained were dried in a fluid bed dryer until the loss-on-drying (LOD) was 1.5% or less.
The dried granules were passed through an oscillating granulator. The milled granulates were mixed with the microcrystalline cellulose, croscarmellose sodium and silicon dioxide in a blender. The blend obtained was then mixed with magnesium stearate. By compressing the mixture using tabletting equipment, tablets were prepared for each potency having the composition as shown in Table 3.

75mg 150mg 300mg Ingredients potency (mg) potency (M;) Irbesartan 75.0 150.0 300.0 Povidone (PVP K-30) 2.0 4.0 8.0 Pregelatinized Starch (Starch 1500) 8.0 16.0 24.0 Poloxamer 188 2.0 4.0 8.0 Microcrystalline Cellulose (Avicel PH
7.5 15.0 30.0 102) Croscarmellose Sodium (Ac-Di-Sol) 4.0 8.0 16.0 Silicon Dioxide (syloid 244) 0.5 1.0 2.0 Magnesium Stearate 1.0 2.0 4.0 Total tablet weight 100.0 200.0 400.0 [0033] Tablets of each potency were tested for dissolution according to the U.S.
Pharmacopeia, using USP apparatus 2 and placing the tablet in 1000 ml of 0.1 hydrochloric acid at 37 C with paddle speed of 50 rpm. The dissolution results are set forth in Table 3A.

Dissolution Results In %
Time In Minutes % Dissolve % Dissolve [0034] This example illustrates the preparation of tablets containing 80%
irbesartan.
[0035] Tablets containing irbesartan were prepared in these potencies from the composition of present invention describe in Table 4.
[0036] 75mg irbesartan with a total weight of 94mg per tablet.
[0037] 150mg irbesartan with a total weight of 188mg per tablet.
[0038] 300mg irbesartan with a total weight of 376mg per tablet.

Ingredients Component Concentration (% w/w) Irbesartan Active drug 79.79 Povidone (PVP K-30) Binder 2.13 Pregelatinized Starch (Starch 1500) Binder 6.38 Poloxamer 188 Surfactant 1.06 Microcrystalline Cellulose (Avicel PH 102) Diluent 5.96 Croscarmellose Sodium (Ac-Di-Sol) Disintegrant 3.19 Silicon Dioxide (syloid 244) Antiadherent 0.43 Magnesium Stearate Lubricant 1.06 Total 100.0 100.0 [0039] Using the above formulation the tablets were prepared by a wet granulation process as a method analogous to that of Example 1. The composition of this formulation is presented in Table 5.

75mg 150mg 300mg Ingredients potency potency potency (mg) (mg) (m) Irbesartan 75.0 150.0 300.0 Povidone (PVP K-30) 2.0 4.0 8.0 Pregelatinized Starch (Starch 1500) 6.0 12.0 24.0 Poloxamer 188 1.0 2.0 4.0 Microcrystalline Cellulose (Avicel PH 102) 5.6 11.2 22.4 Croscarmellose Sodium (Ac-Di-Sol) 3.0 6.0 12.0 Silicon Dioxide (syloid 244) 0.4 0.8 1.6 Magnesium Stearate 1.0 2.0 4.0 Total tablet weight 94.0 188.0 376.0 [0040] Tablets of each potency were tested for dissolution according to the U.S.
Pharmacopeia, using USP apparatus 2 and placing the tablet in 1000 ml of 0.1 hydrochloric acid at 37 C with paddle speed of 50 rpm. The % irbesartan in the formulation dissolved over time is set forth in Table 5A.

Dissolution Results In %
Time In Minutes % Dissolve % Dissolve % Dissolve [0041] This example illustrates the preparation of tablets comprising irbesartan in an amount of approximately 80% by weight of the formulation, and hydrochlorothiazide in an amount of approximately 3.32% -6.65% by weight of the formulation.
[0042] Tablets containing irbesartan and hydrochlorothiazide were prepared in various potencies in accordance with the present invention as described in Table 6.
[0043] The tablets a) comprise 1 50mg irbesartan and 12.5 mg hydrochlorothiazide with a total weight of 188mg per tablet and b) comprise 300mg irbesartan and 12.5 mg hydrochlorothiazide with a total weight of 376mg per tablet.

Ingredients Component Concentration Concentration ( /o w/w (/o w/w) Irbesartan Active drug 79.79 79.79 Hydrochlorothiazide Active drug 6.65 3.32 Pregelatinized Starch (Starch Binder 3.19 4.12 1500) Povidone (PVP K-30) Binder 2.13 2.13 Microcrystalline Cellulose 3.56 (Avicel PH 102) Diluent 5.96 Croscarmellose Sodium (Ac-Di- Disintegrant 3.19 3.19 Sol) Silicon Dioxide (syloid 244) Antiadherent 0.43 0.43 Magnesium Stearate Lubricant 1.06 1.06 Total 100.0 100.0 100.0 [0044] Using the above formulation, tablets were prepared by wet granulation.
Irbesartan and hydrochlorothiazide were mixed in a high shear mixer (Diosna). This mixture was mixed with pregelatinized starch and then granulated with the granulating fluid of povidone in purified water. The granules obtained were dried in a fluid bed dryer until the loss-on-drying (LOD) is 1.5% or less. The dried granules were passed through an oscillating granulator. The milled granulates were mixed with the microcrystalline cellulose, croscarmellose sodium and silicon dioxide in a blender. The blend obtained was then mixed with magnesium stearate. By compressing the mixture using tabletting equipment, tablets were prepared for each potency having the composition as shown in the table above.

[0045] This example illustrates another formulation containing irbesartan and hydrochlorothiazide in accordance with the invention. The formulations were made by wet granulation, as described above.

150mg/12.5 300mg/12.5 Ingredients mg potency mg potency (mg) (mg) Irbesartan 150.0 300.0 Hydrochlorothiazide 12.5 12:5 Pregelatinized Starch (Starch 6.0 15.5 1500) Povidone (PVP K-30) 4.0 8.0 Microcrystalline Cellulose (Avicel PH 102) 6.7 22.4 Croscarmellose Sodium (Ac-Di-Sol) 6.0 12.0 Silicon Dioxide (syloid 244) 0.8 1.6 Magnesium Stearate 2.0 4.0 Total tablet weight 188.0 376.0 [0046] This example illustrates another formulation containing irbesartan and hydrochlorothiazide in accordance with the invention. The formulations were made by wet granulation as described above.

300mg/12.5 Concentration 150mg/12.5 Concentration Ingredients mg potency (% w/w) mg potency (% w/w) (mg) (mg) Irbesartan 300.0 79.79 150 79.79 Hydrochlorothiazide 12.5 3.32 12.5 6.65 Pregelatinized Starch 3.19 6.0 3.19 (Starch 1500) 12.0 Povidone (PVP K-30) 8.0 2.13 4.0 2.13 Microcrystalline 5.29 3.7 1.96 Cellulose 19.9 (Avicel PH 102) Croscarmellose Sodium 18.0 4.79 9.0 4.79 (Ac-Di-Sol) Silicon Dioxide 1 6 0.43 0.8 0.43 (syloid 244) Magnesium Stearate 4.0 1.06 2.0 1.06 Total tablet weight 376.0 100.0 188.0 100.0 [00471 This example illustrates another formulation containing irbesartan and hydrochlorothiazide in accordance with the invention. The formulations were made by wet granulation as described above.

150mg/12.5 Concentration 300mg/12.5 Ingredients mg (% w/w) mg potency Concentration potency (mg) (% w/w) (mg) Irbesartan 150.0 79.79 300.0 79.79 Hydrochlorothiazide 12.5 6.65 12.5 3.32 Pregelatinized Starch 6.0 3.19 12.0 (Starch 1500) 3.19 Povidone (PVP K-30) 4.0 2.13 8.0 2.13 Poloxamer 188 2.0 1.06 4.0 1.06 Microcrystalline Cellulose 3.7 1.97 19.9 (Avicel PH 102) 5'29 Croscarmellose Sodium 7.0 3.72 14.0 3.72 (Ac-Di-Sol) Silicon Dioxide 0.8 0.43 1.6 0.43 (syloid 244) Magnesium Stearate 2.0 1.06 4.0 1.06 Total 188.0 100.0 376.0 100.0 10048]

100491 Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims (38)

1. A composition comprising greater than 70% w/w irbesartan, a binder and a surfactant.
2. The composition of claim 1, which exhibits a dissolution profile according to which greater than about 85% of the irbesartan is dissolved within about 30 minutes using USP
apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37°C with paddle speed of 50 rpm.
3. The composition of claim 2, which comprises greater than 75% w/w irbesartan.
4. The composition of any one of claims 1 to 3, in the form of a tablet.
5. The composition of any one of claims 1 to 4, wherein the binder is povidone or pregelatinized starch.
6. The composition of claim 5, wherein the binder is povidone.
7. The composition of claim 6, wherein the povidone is from about 1.0 to about 7.0% w/w of the composition.
8. The composition of any of claims 1 to 7, wherein the binder is pregelatinized starch.
9. The composition of claim 8, wherein the pregelatinized starch is from about 1.0 to about
10.0% w/w of the composition.

10. The composition of any one of claims 1 to 9, wherein said composition comprises a disintegrant.
11. The composition of claim 10, wherein the disintegrant is croscarmellose sodium.
12. The composition of claim 11, wherein the croscarmellose sodium is from about-1.0 to about 7.0% w/w of the composition.
13. The composition of any one of claims 1 to 12, wherein the surfactant is poloxamer 188.
14. The composition of claim 13, wherein the poloxamer 188 is from about 0.2 to about 6.0%
w/w of the composition.
15. The composition of any one of claims 1 to 14, wherein said composition comprises a diluent.
16. The composition of claim 15, wherein said diluent is microcrystalline cellulose.
17. The composition of claim 16, wherein the microcrystalline cellulose is from about 2.0 to about 10.0% w/w of the composition.
18. The composition of any one of claims I to 17, wherein said composition comprises an antiadherent.
19. The composition of claim 18, wherein the antiadherent is silicon dioxide.
20. The composition of claim 19, wherein the silicon dioxide is from about-0 4% w/w to about 0.5% w/w of the composition.
21. The composition of any one of claims 1 to 20, wherein said composition comprises a lubricant.
22. The composition of claim 21, wherein said lubricant is magnesium stearate.
23. The composition of claim 22, wherein the magnesium stearate is from about 0.2 to about 2.0% w/w of the composition.
24. The composition of any one of claims 1 to 23, further wherein said composition comprises at least one additional active pharmaceutical agent.
25. The composition of claim 24, wherein the additional active pharmaceutical agent is a diuretic agent.
26. The composition of claim 24 or 25, wherein the additional active agent is hydrochlorothiazide.
27. The composition of claim 1, wherein the composition comprises, by weight, 75%
irbesartan, and by weight, about 10% binder, about 7.5% diluent, about 4%
disintegrant, about 2% surfactant, about 1% lubricant, and about 0.5% antiadherent; wherein said binder consists of pregclantinized starch and povidone; said diluent is microcrystalline cellulose, said disintegrant is croscarmellose sodium, said surfactant is poloxamer 188, said lubricant is magnesium stearate, and said antiadherent is silicon dioxide.
28. The composition of claim 1, wherein the composition comprises, by weight, 79.79%
irbesartan, and the pharmaceutical excipients comprise, by weight, about 8.5%
binder, about 5.9% diluent, about 3.1 % disintegrant, about 1% surfactant, about 1%
lubricant, and about 0.5% antiadherent; wherein said binder consists of pregelantinized starch and povidone; said diluent is microcrystalline cellulose, said disintegrant is croscarmellose sodium, said surfactant is poloxamer 188, said lubricant is magnesium stearate, and said antiadherent is silicon dioxide.
29. The composition of claim 27 or 28, wherein said composition is a tablet, such that the tablet has a dissolution performance such that greater than 85% of the irbesartan contained therein dissolves within 30 minutes under the following conditions:
USP
apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37°C with paddle speed of 50 rpm.
30. The composition of claim 1, which exhibits a dissolution profile according to which greater than about 80% of the irbesartan is dissolved within about 10 minutes using USP
apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37°C with paddle speed of 50 rpm.
31. The composition of claim 1, which exhibits a dissolution profile according to which greater than about 85% of the irbesartan is dissolved within about 10 minutes using USP
apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37°C with paddle speed of 50 rpm.
32. The composition of claim 1, which exhibits a dissolution profile according to which at least about 75% of the irbesartan is dissolved within about 5 minutes, at least about 85%

of the irbesartan is dissolved within about 10 minutes, and at least about 95%
of the irbesartan is dissolved within about 20 minutes using USP apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37°C with paddle speed of 50 rpm.
33. The composition of claim 1, wherein the composition comprises, by weight, 79.79%
irbesartan, from about 3% to about 7% hydrochlorothiazide, from about 5.3% to about 7.5% binder, from about 3.5% to about 6% diluent, from about 3% to about 3.2%
disintegrant, from about 1% to about 1.1 % lubricant, and from about 0.4% to about 0.5%
antiadherent; wherein said binder consists of pregelantinized starch and povidone; said diluent is microcrystalline cellulose, said disintegrant is croscarmellose sodium, said lubricant is magnesium stearate, and said antiadherent is silicon dioxide.
34. The composition of claim 32, wherein the composition comprises, by weight, 79.79%
irbesartan, 2.13% povidone, 6.38% pregelatinized starch, 3.15% croscarmellose sodium, 1.01% poloxamer 188,5.96% microcrystal line cellulose, 1.01% magnesium stearate and 0.43% silicon dioxide.
35. The composition of claim 33, wherein the composition comprises 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
36. The composition of claim 1, wherein the composition comprises, by weight, about 79%
irbesartan, about 3.3% hydrochlorothiazide, about 3.1 % pregelatinized starch, about 2.1 %
povidone, about 5.3% microcrystalline cellulose, about 4.7% croscarmellose sodium, about 0.4% silicon dioxide and about 1% magnesium stearate.
37. The tablet of claim 4, wherein the tablet is prepared by a wet granulation method.
38. The composition of claim 8 or 9, wherein the pregelatinized starch is starch 1500.TM..
CA2568640A 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan Expired - Fee Related CA2568640C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57742704P 2004-06-04 2004-06-04
US60/577,427 2004-06-04
PCT/IB2005/002689 WO2005118166A2 (en) 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan

Publications (2)

Publication Number Publication Date
CA2568640A1 CA2568640A1 (en) 2005-12-15
CA2568640C true CA2568640C (en) 2011-08-09

Family

ID=35463389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2568640A Expired - Fee Related CA2568640C (en) 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan

Country Status (11)

Country Link
US (2) US8226977B2 (en)
EP (1) EP1750862B1 (en)
JP (2) JP4880591B2 (en)
AT (1) ATE493973T1 (en)
AU (1) AU2005249794A1 (en)
CA (1) CA2568640C (en)
DE (1) DE602005025755D1 (en)
ES (1) ES2282062T1 (en)
IL (1) IL179718A0 (en)
PL (1) PL1750862T3 (en)
WO (1) WO2005118166A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806130B1 (en) * 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising irbesartan
DE102006006588A1 (en) * 2006-02-13 2007-08-16 Ratiopharm Gmbh Fast-release irbesartan-containing pharmaceutical composition
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
JP5527921B2 (en) * 2006-12-22 2014-06-25 エスエス製薬株式会社 Oral solid composition concealing bitterness
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
US20090048317A1 (en) * 2007-08-01 2009-02-19 Michael Fox Formulations of candesartan
PT2065035E (en) 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Pharmaceutical formulations containing irbesartan
JP5296456B2 (en) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
WO2011010316A1 (en) * 2009-07-20 2011-01-27 Hetero Research Foundation Pharmaceutical compositions of irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
JP5946135B2 (en) * 2012-03-29 2016-07-05 塩野義製薬株式会社 Solid formulation containing trichloromethiazide and crystalline cellulose
JP6018420B2 (en) * 2012-06-05 2016-11-02 ニプロ株式会社 Pharmaceutical composition comprising an angiotensin II receptor antagonist and thiazide diuretic
KR20140030505A (en) * 2012-08-31 2014-03-12 한미약품 주식회사 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
JP5714652B2 (en) * 2013-06-13 2015-05-07 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP5978335B2 (en) * 2015-03-11 2016-08-24 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP6445923B2 (en) * 2015-04-22 2018-12-26 ダイト株式会社 Preparation of irbesartan-containing tablets
JP6737060B2 (en) * 2015-09-11 2020-08-05 ニプロ株式会社 Method for producing pharmaceutical composition containing irbesartan
JP6151413B2 (en) * 2016-07-25 2017-06-21 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP7157752B2 (en) 2017-02-17 2022-10-20 エイドス セラピューティクス，インコーポレイティド Methods for the preparation of AG-10, intermediates thereof and salts thereof
JP2017141299A (en) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet
JP2018168185A (en) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition and orally disintegrable tablet with excellent elution
MA53238A (en) * 2018-08-17 2022-04-13 Eidos Therapeutics Inc AG10 FORMULAS
JP2019203031A (en) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet

Family Cites Families (371)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327080A (en) 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US5049394A (en) 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5212165A (en) 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2681067B1 (en) 1991-09-10 1993-12-17 Elf Sanofi N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2665702B1 (en) 1990-08-08 1994-02-25 Sanofi N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2659967B1 (en) 1990-03-20 1992-07-24 Sanofi Sa N-SUBSTITUTED IMIDAZOLINONE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5137902A (en) 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
US5089626A (en) * 1990-08-23 1992-02-18 Merck & Co., Inc. Process for preparing an angiotensin II antagonist
US5098889A (en) * 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
US5032578A (en) 1990-09-17 1991-07-16 E. R. Squibb & Sons, Inc. Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
ATE177634T1 (en) 1990-12-14 1999-04-15 Smithkline Beecham Corp ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS
US20010016594A1 (en) 1990-12-14 2001-08-23 Smithkline Beecham P.L.C. Medicament
US6028091A (en) * 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
FR2673427B1 (en) 1991-03-01 1993-06-18 Sanofi Elf N-SUBSTITUTED DIAZOTATED HETEROCYCLIC DERIVATIVES BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2677984B1 (en) 1991-06-21 1994-02-25 Elf Sanofi N-SUBSTITUTED IMIDAZOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
DK0521388T3 (en) * 1991-07-01 1995-09-11 Gergely Gerhard Process for the preparation of a pharmaceutical composition having at least two different active substances and the use of such a preparation
AU2496492A (en) 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
CA2115990A1 (en) 1991-08-19 1993-03-04 George Albert Boswell Angiotensin ii receptor blocking imidazolinone derivatives
EP0553777B1 (en) * 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
FR2688781B1 (en) 1992-03-23 1994-07-01 Sanofi Elf IMIDAZOLINES N-SUBSTITUTED BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB9208116D0 (en) 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
US6673824B1 (en) * 1992-05-06 2004-01-06 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
EP0577023A3 (en) 1992-07-01 1996-12-18 Hoechst Ag Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
US5457112A (en) 1992-12-14 1995-10-10 Synthelabo 3-(6-quinolylmethyl)-4H-imidazol-4-one derivatives, their preparation and their application in therapy
WO1994018954A1 (en) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0635263A3 (en) 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue.
FR2708608B1 (en) 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
FR2708606B1 (en) 1993-07-30 1995-10-27 Sanofi Sa N-phenylalkylindol-2-one derivatives, their preparation, pharmaceutical compositions containing them.
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5824696A (en) 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US6174917B1 (en) * 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
CA2176927C (en) * 1993-11-17 2010-03-23 Seang H. Yiv Transparent liquid for encapsulated drug delivery
US5536505A (en) 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
US5523095A (en) 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
CN1140409A (en) * 1994-02-08 1997-01-15 希巴-盖吉股份公司 Treatment of normotensive glaucoma with angiotensin II antagonisto
JP3414539B2 (en) * 1994-05-11 2003-06-09 有限会社ドット Composition for nasal absorption
US6645463B1 (en) 1994-05-16 2003-11-11 The Board Of Regents Of The University Of Michigan Blood-pool selective carrier for lipophilic imaging agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5541209A (en) 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
FR2725987B1 (en) 1994-10-19 1997-01-10 Sanofi Sa PROCESS FOR THE PREPARATION OF A TETRAZOLE DERIVATIVE IN TWO CRYSTALLINE FORMS AND NOVEL CRYSTALLINE FORM THEREOF
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5780473A (en) 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
CA2168066A1 (en) 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
FR2732223B1 (en) * 1995-03-30 1997-06-13 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US20020094346A1 (en) 1995-05-17 2002-07-18 M. D. Henry C. Lin Method and compositions for improving digestion and absorption in the small intestine
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SE9501881D0 (en) 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII receptor antagonists
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DK0831910T3 (en) 1995-06-07 2002-05-21 Searle & Co Combination therapy with epoxy steroid aldosterone antagonist and angiotensin II receptor antagonist for the treatment of congestive heart failure
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
FR2735365B1 (en) 1995-06-14 1997-09-05 Sanofi Sa USE OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURANE DERIVATIVE FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS
SE9502219D0 (en) 1995-06-19 1995-06-19 Astra Ab Novel medical use
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
FR2740136B1 (en) 1995-10-24 1998-01-09 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2740686B1 (en) 1995-11-03 1998-01-16 Sanofi Sa STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION
WO1997031634A1 (en) * 1996-02-29 1997-09-04 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis
FR2746013B1 (en) 1996-03-18 1998-05-29 Sanofi Sa USE OF ANTIARRHYTHMIC COMPOUNDS IN THE PREVENTION OF POST INFARCT MORTALITY
US5939446A (en) 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
KR100540618B1 (en) * 1996-07-15 2006-01-12 상꾜 가부시키가이샤 Medicinal compositions
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6019988A (en) * 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
FR2757157B1 (en) 1996-12-13 1999-12-31 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
EP0855392A3 (en) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
AU6187898A (en) 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5846985A (en) 1997-03-05 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
TW580397B (en) 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
DE19724696A1 (en) 1997-06-12 1998-12-24 Hexal Ag Pharmaceutical preparation with three types of pellets
EP0986373B1 (en) * 1997-06-13 2004-03-17 Nanopharm AG Drug targeting system, method of its preparation and its use
IT1292437B1 (en) 1997-06-30 1999-02-08 Zambon Spa ORTHO-METALLATION PROCESS USEFUL FOR THE SYNTHESIS OF 1 - TETRAZOL- 5-IL) 2-SUBSTITUTED BENZENES
HU218679B (en) 1997-07-25 2000-10-28 Sanofi-Synthelabo Process for preparation of imidazolones and intermediates thereof
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
GT199800126A (en) 1997-08-29 2000-01-29 COMBINATION THERAPY.
NL1006903C2 (en) * 1997-09-01 1999-03-04 Johannes Gerardus Van Gemert Method for compacting molding sand.
NZ335676A (en) 1997-09-09 2001-03-30 Select Release L Coated particles comprising an exterior coating and a matrix comprising a liquid phase or liquid crystalline phase which is nanostructured
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
KR100572080B1 (en) 1997-10-17 2006-04-17 유로진 리미티드 The use of inhibitors of the renin-angiotensin system
JPH11137208A (en) * 1997-11-14 1999-05-25 Nikken Chem Co Ltd Solid material rapidly soluble in oral cavity and its production
DE19750529A1 (en) * 1997-11-14 1999-05-20 Basf Ag New heterocyclic alpha-hydroxycarboxylic acid derivatives useful for treating hypertension, chronic coronary insufficiency, asthma, prostate cancer etc.
HUP0100469A2 (en) * 1997-12-19 2001-08-28 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
US6162922A (en) 1998-01-30 2000-12-19 Bristol-Myers Squibb Co. Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6300356B1 (en) 1998-02-25 2001-10-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
WO1999044590A1 (en) 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
FR2775598A1 (en) 1998-03-06 1999-09-10 Sanofi Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS
US6284363B1 (en) 1998-03-23 2001-09-04 Fuji Polymer Industries Co., Ltd. Electromagnetic wave absorbing thermoconductive silicone gel molded sheet and method for producing the same
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
FR2778103A1 (en) 1998-04-29 1999-11-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
NZ508066A (en) 1998-05-11 2003-03-28 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
CA2332608C (en) 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
IT1301759B1 (en) 1998-06-19 2000-07-07 Nicox Sa NITRATED SALTS OF ANTI-HYPERTENSIVE DRUGS
FR2780403B3 (en) * 1998-06-24 2000-07-21 Sanofi Sa NOVEL FORM OF IRBESARTAN, METHODS FOR OBTAINING SAID FORM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
FR2780890B3 (en) 1998-07-10 2000-09-01 Sanofi Sa USE OF A PHARMACEUTICAL COMPOSITION CONTAINING, IN COMBINATION, AN ANTAGONIST OF ANGIOTENSIN II AT1 RECEPTORS AND INDOMETHACIN FOR THE TREATMENT OF CHRONIC GLOMERULONEPHRITES
EP1561458B1 (en) 1998-07-28 2010-09-15 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US6284763B1 (en) 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
FR2783422A1 (en) 1998-09-21 2000-03-24 Sanofi Sa Composition for reducing treating hypertension or platelet aggregation disorders, contains angiotensin II receptor antagonist and platelet anti-aggregation agent
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6641565B1 (en) * 1998-11-13 2003-11-04 Elan Pharma International Limited drug delivery systems and methods
TNSN99224A1 (en) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc METHODS OF REDUCING GLUCOSE AND TRIGLYCERIDE LEVELS IN SERUM AND FOR ANTIGENESIS SUPPRESSION USING INDOLEALKANOIC ACIDS
FR2787330A1 (en) 1998-12-18 2000-06-23 Sanofi Sa Compositions containing an immunosuppressant and an AT1 angiotensin II receptor antagonist, for prevention and treatment of vascular complications due to graft rejection
KR100349597B1 (en) 1999-01-12 2002-08-22 삼성전자 주식회사 Optical wave-guide device and manufacturing method thereof
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
ATE306489T1 (en) 1999-03-08 2005-10-15 Medicure Inc PYRIDOXAL ANALOGUE FOR THE TREATMENT OF DISORDERS CAUSED BY VITAMIN B6 DEFICIENCY
JP3695978B2 (en) 1999-03-16 2005-09-14 三洋電機株式会社 Alkaline storage battery with spiral electrode body
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
KR20020013936A (en) * 1999-06-25 2002-02-21 추후제출 Substituted phenoxyacetic acids
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
SE9902597D0 (en) 1999-07-06 1999-07-06 Astra Ab New use
EP1210117A2 (en) * 1999-08-24 2002-06-05 Medicure International Inc. Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
US6555551B1 (en) 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20030225124A1 (en) 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
AU7365900A (en) 1999-09-08 2001-04-10 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001028548A1 (en) 1999-10-19 2001-04-26 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
EP1093814A1 (en) 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
CA2386954C (en) 1999-10-29 2011-12-13 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US20030113330A1 (en) 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1106210A3 (en) * 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
FR2803525B1 (en) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic SIGNAL TRANSDUCTION INHIBITOR OF HETEROTRIMERIC PROTEINS ASSOCIATED WITH AN ANTI-HYPERTENSION AGENT IN THE TREATMENT OF ARTERIAL HYPERTENSION
WO2001054694A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
AU3408801A (en) * 2000-02-18 2001-08-27 Takeda Chemical Industries Ltd Tnf-alpha inhibitors
EP1258254A4 (en) 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
US20030152636A1 (en) 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
US6605612B2 (en) 2000-02-29 2003-08-12 Medicure International Inc. Cardioprotective phosohonates and malonates
AU2001238718A1 (en) 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
CZ20023121A3 (en) 2000-03-17 2003-05-14 Ajinomoto Co., Inc. Pharmaceutical preparations intended for treating diabetic complications and neuropathy and use of such preparations
US6436684B1 (en) 2000-03-27 2002-08-20 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
DE10014588A1 (en) 2000-03-27 2001-10-04 Basf Ag Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone
US20020022587A1 (en) * 2000-03-28 2002-02-21 Ferguson Alastair V. Methods for effecting neuroprotection
CA2403903A1 (en) 2000-03-28 2002-09-26 Masatoshi Hazama Angiogenesis inhibitors
DE10015479A1 (en) 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
CA2405496A1 (en) * 2000-04-03 2001-10-11 Richard A. Reeves Vasopeptidase inhibitors to treat isolated systolic hypertension
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
AU2001253401B2 (en) * 2000-04-11 2006-12-07 Atherogenics, Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US20030083342A1 (en) 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
KR20020089433A (en) * 2000-04-12 2002-11-29 노파르티스 아게 Combination of Organic Compounds
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
AR030557A1 (en) 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
ES2303527T3 (en) * 2000-05-10 2008-08-16 Jagotec Ag GRINDING PROCEDURE.
AU5959201A (en) * 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
WO2001089519A1 (en) * 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
WO2001090067A1 (en) 2000-05-22 2001-11-29 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
US20020049155A1 (en) 2000-05-31 2002-04-25 Hogenkamp Henricus P.C. Cobalamin compounds useful as cardiovascular agents and as imaging agents
US20030212124A1 (en) 2001-05-30 2003-11-13 Kevorkian Robert C. Use of ace inhibitors for treatment of patients suffering from behavioral disorders
US7678387B2 (en) 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
DE10029201A1 (en) * 2000-06-19 2001-12-20 Basf Ag Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature
AU7007001A (en) * 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use
WO2002000258A1 (en) 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy
US20030114420A1 (en) 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US7799794B2 (en) * 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
AU2001279284A1 (en) 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
NZ523815A (en) 2000-07-07 2004-07-30 Medicure Int Inc Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US20030176426A1 (en) 2000-07-13 2003-09-18 Alteon, Inc. Method for treating fibrotic diseases or other indications with imidazolium agents
CA2429008A1 (en) 2000-07-13 2003-01-09 Takeda Chemical Industries, Ltd. Lipid-rich plaque regressing agents
JP2004504389A (en) 2000-07-13 2004-02-12 アルテオン　インコーポレーテッド Cyanomethyl-substituted thiazolium and imidazolium, and treatment of diseases associated with protein aging
EP1368009A2 (en) 2000-07-27 2003-12-10 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
GB0020691D0 (en) 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20030187038A1 (en) 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
US6521747B2 (en) 2000-08-28 2003-02-18 Genaissance Pharmaceuticals, Inc. Haplotypes of the AGTR1 gene
CA2420844A1 (en) 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
EP1313451B1 (en) 2000-08-31 2009-03-11 Jagotec AG Milled particles
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
US6595926B1 (en) 2000-09-07 2003-07-22 John H. Laragh Method for evaluating and treating hypertension
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
WO2002034248A2 (en) 2000-10-20 2002-05-02 Boehringer Ingelheim Pharmaceuticals, Inc. METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION
JP2004512327A (en) 2000-10-26 2004-04-22 ファイザー・プロダクツ・インク Pyrimidine-2,4,6-trione metalloproteinase inhibitor
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2002040054A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Pharmaceutical preparation containing copolyvidone
AU2002237664A1 (en) 2000-11-20 2002-05-27 Bristol-Myers Squibb Company Pyridone derivatives as AP2 inhibitors
JP4107831B2 (en) 2000-11-21 2008-06-25 第一三共株式会社 Pharmaceutical composition
DE60131569T2 (en) 2000-11-28 2008-10-23 The University Of Chicago, Chicago GENETICALLY MODIFIED HERPES VIRUS FOR THE TREATMENT OF HEART AND VASCULAR DISEASES
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
EP2062593A3 (en) * 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive peptide
WO2002043807A2 (en) 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
AU2002241736A1 (en) 2000-12-21 2002-07-01 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
JP4035052B2 (en) 2000-12-28 2008-01-16 キッセイ薬品工業株式会社 Glucopyranosyloxypyrazole derivative and its pharmaceutical use
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc Method for treating fibrotic diseases or other indications
EP1355645A4 (en) 2000-12-29 2005-02-23 Alteon Inc Method for treating fibrotic diseases or other indications iiic
WO2002053101A2 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
ITMI20010129A1 (en) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
ATE381347T1 (en) 2001-01-26 2008-01-15 Schering Corp COMBINATIONS OF EZETIMIBE AND ASPIRIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA2434436A1 (en) 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AU2002240050A1 (en) 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA2436774A1 (en) 2001-01-30 2002-08-08 R. Michael Lawrence Sulfonamide lactam inhibitors of factor xa
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
FI114483B (en) * 2001-02-20 2004-10-29 Jurilab Ltd Oy Procedure for detecting a risk of elevated blood pressure and its uses
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
CA2438595C (en) 2001-02-27 2011-08-09 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
US20030119010A1 (en) 2001-03-01 2003-06-26 University Of Queensland Polynucleotides and polypeptides linked to a disease or condition
EP1363631A4 (en) 2001-03-02 2005-11-16 Bristol Myers Squibb Co Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
JP2005506286A (en) 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー Combined administration of melanocortin receptor agonist and phosphodiesterase inhibitor for the treatment of cyclic-AMP related diseases
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6642244B2 (en) 2001-03-16 2003-11-04 Bristol-Myers Squibb Co. Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
JP2004528319A (en) 2001-03-30 2004-09-16 ファイザー・プロダクツ・インク Pyridazinone aldose reductase inhibitor
WO2002083066A2 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US20030004199A1 (en) * 2001-04-12 2003-01-02 Isabelle Ounis Method for preventing or treating pulmonary inflammation by administering an endothelin antagonist
WO2002083074A2 (en) 2001-04-13 2002-10-24 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
AU2002311859A1 (en) 2001-04-26 2002-11-11 Vanderbilt University Compositions and methods for treating colorectal polyps and cancer
EP1406608B1 (en) 2001-05-02 2009-07-29 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
US20020168393A1 (en) 2001-05-08 2002-11-14 Ryota Sugimoto Implantable medical material and implantable medical device
CA2445913A1 (en) 2001-05-14 2003-10-29 Merck & Co., Inc. Method of treatment
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20030078190A1 (en) 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US20030092736A1 (en) 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US20030027820A1 (en) * 2001-05-30 2003-02-06 Alteon, Inc. Method for treating fibrotic diseases or other indications V
CA2448294A1 (en) * 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications vi
US20040156903A1 (en) 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
AR034518A1 (en) 2001-06-18 2004-02-25 Noven Pharma INCREASE IN THE TRANSDERMAL ADMINISTRATION OF A PHARMACO
US6919323B2 (en) * 2001-07-13 2005-07-19 Bristol-Myers Squibb Company Pyridazinone inhibitors of fatty acid binding protein and method
US20030158090A1 (en) 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US6670386B2 (en) * 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1425015A4 (en) 2001-08-20 2004-12-15 Bristol Myers Squibb Co Tetrahydroquinoline derivatives as antithrombotic agents
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6969719B2 (en) 2001-08-28 2005-11-29 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
EP1432720A1 (en) 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
JP2005502367A (en) 2001-09-11 2005-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト Expression profiling in the intact human heart
US6638542B2 (en) 2001-09-20 2003-10-28 Nutricia N.V. Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20030119808A1 (en) 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030114469A1 (en) 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
EP1435973A4 (en) 2001-09-28 2007-05-02 Mayo Foundation Coadministration of transport protein with conjugated cobalamin to deliver agents
EP1298223A3 (en) 2001-09-28 2003-07-23 Pfizer Products Inc. Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
CA2463908A1 (en) 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
FR2831446B1 (en) 2001-10-26 2004-03-05 Sanofi Synthelabo USE OF IRBESARTAN FOR THE PREPARATION OF MEDICINES USEFUL FOR THE PREVENTION OR TREATMENT OF PULMONARY HYPERTENSION
AU2916902A (en) 2001-10-29 2003-05-01 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Glycogen synthase kinase function in endothelial cells
US20030083614A1 (en) 2001-10-30 2003-05-01 Boehringer Ingelheim Pharma Kg Controlled release endoprosthetic device
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
US6673815B2 (en) * 2001-11-06 2004-01-06 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1442042A1 (en) 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
TW200300347A (en) 2001-11-13 2003-06-01 Schering Corp Nk1 antagonists
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20050176793A1 (en) 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
PE20030762A1 (en) 2001-12-18 2003-09-05 Schering Corp HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
US7087636B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
JP2005516940A (en) 2001-12-20 2005-06-09 ブリストル−マイヤーズ　スクイブ　カンパニー Reduction of pulse pressure and vascular stiffness by administration of vascular peptidase inhibitor to hypertensive patients
US7011846B2 (en) 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
EP1790353A1 (en) 2001-12-29 2007-05-30 Novo Nordisk A/S Combined use of a GLP-1 compound and a modulator of diabetic late complications
ES2485841T3 (en) 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compounds containing phosphorus and uses thereof
ATE469167T1 (en) 2002-02-06 2010-06-15 Vicor Technologies Inc ANTI-INFARCH MOLECULES
US20030221207A1 (en) 2002-02-13 2003-11-27 Pharmacia Corporation, Global Patent Department Cardiac-specific 11beta hydroxysteroid dehydrogenase type 2 transgenic mice
WO2003070278A1 (en) 2002-02-19 2003-08-28 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
WO2003071870A1 (en) 2002-02-26 2003-09-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US20040116510A1 (en) 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
JP2005526769A (en) 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Central airway administration for systemic delivery of therapeutic agents
MXPA04005555A (en) 2002-03-18 2005-05-16 Pfizer Prod Inc Methods of treatment with selective ep4 receptor agonists.
US20030199424A1 (en) 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
WO2003086282A2 (en) 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
EP1501833B1 (en) * 2002-04-26 2005-11-02 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
JP2005528408A (en) * 2002-04-26 2005-09-22 シエーリング アクチエンゲゼルシャフト Treatment of hypertension in women undergoing hormone replacement therapy
BR0309556A (en) 2002-04-26 2005-02-09 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors
JP2005527598A (en) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (en) * 2002-04-26 2005-07-08 Pfizer Prod Inc INHIBITORS OF TRIARILOXIARILOXIPIRIMIDIN-2,4,6-METALOPROTEINASE TRION.
US20030203027A1 (en) 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US20030203019A1 (en) 2002-04-30 2003-10-30 Cornelius John Mark Coated conditioners for use in foods and pharmaceuticals
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7276514B2 (en) 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
AUPS236902A0 (en) 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7375138B2 (en) 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003099206A2 (en) 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
US20030229007A1 (en) 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
TW200404802A (en) 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
US20030233118A1 (en) 2002-06-13 2003-12-18 Hui John C. K. Method for treating congestive heart failure using external counterpulsation
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US7049333B2 (en) * 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US7763278B2 (en) 2002-06-10 2010-07-27 Elan Pharma International Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
WO2003106628A2 (en) * 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
US6846838B2 (en) * 2002-06-19 2005-01-25 Bristol-Myers Squibb Company Ureido-substituted aniline compounds useful as serine protease inhibitors
EP1382334A1 (en) 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
ATE458534T1 (en) 2002-10-04 2010-03-15 Microchips Inc MEDICAL DEVICE FOR CONTROLLED DRUG ADMINISTRATION AND CARDIAC MONITORING AND/OR HEART STIMULATION
US20040106954A1 (en) 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7268157B2 (en) 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity

Also Published As

Publication number Publication date
DE602005025755D1 (en) 2011-02-17
EP1750862A4 (en) 2008-06-11
JP2011252022A (en) 2011-12-15
WO2005118166A3 (en) 2006-07-27
US20120238555A1 (en) 2012-09-20
PL1750862T3 (en) 2011-06-30
JP4880591B2 (en) 2012-02-22
US8226977B2 (en) 2012-07-24
US20050271720A1 (en) 2005-12-08
CA2568640A1 (en) 2005-12-15
ATE493973T1 (en) 2011-01-15
ES2282062T1 (en) 2007-10-16
EP1750862A2 (en) 2007-02-14
JP2008501680A (en) 2008-01-24
WO2005118166A2 (en) 2005-12-15
AU2005249794A1 (en) 2005-12-15
IL179718A0 (en) 2007-05-15
EP1750862B1 (en) 2011-01-05
US8414920B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
CA2568640C (en) Pharmaceutical composition containing irbesartan
AU702651B2 (en) Pharmaceutical compositions containing irbesartan
US5994348A (en) Pharmaceutical compositions containing irbesartan
AU2007297333B2 (en) Solid dosage form of olmesartan medoxomil and amlodipine
JP2009515956A (en) Telmisartan pharmaceutical composition
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
CA2644179C (en) Novel pharmaceutical composition comprising a disintegration matrix
WO2009113420A1 (en) Improvement of dissolvability of preparation containing olmesartan medoxomil
US20070116759A1 (en) Pharmaceutical compositions of telmisartan
JP5241511B2 (en) Pharmaceutical composition with improved dissolution
WO2022132067A1 (en) Stable bilayer tablet compositions
KR100482715B1 (en) Pharmaceutical compositions containing irbesartan
KR20090052944A (en) A pharmaceutical composition comprising irbesartan
MXPA96002103A (en) Pharmaceutical compositions containing irbesar
WO2008008057A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150602